Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PledOx for prevention of CIPN in CRC
NCT04034355Phase 3Terminated
- Sponsor
- Egetis Therapeutics
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of calmangafodipir in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Egetis Therapeutics. Started Jan 2019; status: terminated.
02
Drugs
calmangafodipir
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04034355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034355.